Clinical Trial

USFDA approves CLOT Retrieval Devices to help with STROKE

Posted on Updated on

Image result

The U.S. Food and Drug Administration today allowed marketing of two Trevo clot retrieval devices as an initial therapy for strokes due to blood clots (ischemic) to reduce paralysis, speech difficulties and other stroke disabilities. These devices should be used within six hours of symptom onset and only following treatment with a clot-dissolving drug (tissue plasminogen activator or t-PA), which needs to be given within three hours of symptom onset.

“This is the first time FDA has allowed the use of these devices alongside t-PA, which has the potential to help further reduce the devastating disabilities associated with strokes compared to the use of t-PA alone,” said Carlos Peña, Ph.D., director of the division of neurological and physical medicine devices at the FDA’s Center for Devices and Radiological Health. “Now health care providers and their patients have another tool for treating stroke and potentially preventing long-term disability.”

The Trevo device was first cleared by the FDA in 2012 to remove a blood clot and restore blood flow in stroke patients who could not receive t-PA or for those patients who did not respond to t-PA therapy. Today’s action expands the devices’ indication to a broader group of patients.

Trevo is a clot removal device that is inserted through a catheter up into the blood vessel to the site of the blood clot. When the shaped section at the end of the device is fully expanded (up to three to six millimeters in diameter), it grips the clot, allowing the physician to retrieve the clot by pulling it back through the blood vessel along with the device for removal through a catheter or sheath.

Stroke kills nearly 130,000 Americans each year and is the fifth leading cause of death, according to the Centers for Disease Control and Prevention. About 87 percent of all strokes are ischemic strokes. Until now, the only first-line treatment for acute ischemic stroke was t-PA administered intravenously.

The FDA evaluated data from a clinical trial comparing 96 randomly selected patients treated with the Trevo device along with t-PA and medical management of blood pressure and disability symptoms with 249 patients who had only t-PA and medical management. Twenty-nine percent of patients treated with the Trevo device were functionally independent (ranging from no symptoms to slight disability) three months after their stroke, compared to 19 percent of patients who were not treated with the Trevo device.

Risks associated with using the Trevo device include a failure to retrieve the blood clot, device malfunctions including breakage and navigation difficulties, which can potentially damage blood vessels and cause perforation or hemorrhage.

The FDA reviewed the data for Trevo for stroke treatment through the de novo premarket review pathway, a regulatory pathway for devices of a new type with low-to-moderate-risk that are not substantially equivalent to an already legally-marketed device and for which special controls can be developed, in addition to general controls, to provide a reasonable assurance of safety and effectiveness of the devices.

Trevo is manufactured by Concentric Medical Inc. in Mountain View, California.

Source: 1, 2

India bouncing back in clinical trials as new norms spur growth

Posted on Updated on

India has begun to bounce back in clinical trials with the new regulations issued at frequent intervals. This has enabled global pharma and clinical research organisations (CROs) to re-consider conduct of human studies in the country, said Naz Haji, SVP and head of India, Indonesia, Malaysia and Singapore operations, Quintiles.

“This change in regulations specific to clinical trials is progressive for both Indian companies and its patient population. Big pharma has evinced interest and is comfortable to kick start human studies once again in India which was considered a promising hub until end of 2012,” he added.

“However, the government along with the industry will need to reinstate efforts to ensure that the regulatory enforcement system in the country is able to step up the pace of approvals and provide the required clearances in a time bound manner. Clinical trials are important in patient care and therefore we are educating our customers internally that human studies are expected to surge supported by adequate assistance from the Indian regulators,” Haji told Pharmabiz at the sidelines of the DIA Life Sciences IT-enabled business conference held here in Bengaluru.

“Our strategy from a company perspective is to capture new opportunities driven by the government’s regulations and create a patient awareness to opt for clinical trials for their medical needs. So long the global companies whose trials constituted a substantial chunk of India’s clinical research business were unsure of India. The lack of regulations and uncertainty on the required approvals were looming large. But now we are convincing them that the environment is conducive and appropriate for clinical trials”, stated Haji adding that all Indian clinical research companies would need to move on similar lines to convince both multinational majors and the Indian patient population.

As it stands, regulations in India are adequate to ensure traction in clinical trials. There is enough momentum in the last nine months to ensure the prevalence of a comfort zone. Now with the latest guidance issued the Union health ministry early this month permitting clinical trials at hospitals with less than 50 beds and with no restriction on the number of clinical trials an investigator could take up at a time in the country, are expected to give a big impetus to growth, he said.

India is much-sought-after by international drug majors and CROs for human studies. The big benefits in this country are the combination of qualified doctors and patient pool along with the hospital infrastructure. Now with implementation of ICT (information and communication technology), the infrastructure needs are evolving with wireless networks, mobiles, higher-quality video viewing and broader bandwidth connections. For Quintiles too, India is key in its future game plan as we continue to invest in both individuals and infrastructure to serve companies here, said Haji.

Furthermore, global pharma and CROs too are beginning trust the reliability on the Indian regulatory system. Another positive for India is that the government itself is reaching out facilitate partnerships and collaborations. “Therefore, this country is bouncing back as it has emerged out of the dark phase of decline in human studies. We foresee 2017 to be more positive as sponsors making a big comeback,” he noted.

Source: 1

USFDA approves Adlyxin to treat type 2 diabetes

Posted on

Add Alt Text Here

The U.S. Food and Drug Administration approved Adlyxin (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes.

“The FDA continues to support the development of new drug therapies for diabetes management,” said Mary Thanh Hai Parks, M.D., deputy director, Office of Drug Evaluation II in the FDA’s Center for Drug Evaluation and Research. “Adlyxin will add to the available treatment options to control blood sugar levels for those with type 2.”

Type 2 diabetes affects more than 29 million people and accounts for more than 90 percent of diabetes cases diagnosed in the United States. Over time, high blood sugar levels can increase the risk for serious complications, including heart disease, blindness and nerve and kidney damage.

Adlyxin is a glucagon-like peptide-1 (GLP-1) receptor agonist, a hormone that helps normalize blood sugar levels. The drug’s safety and effectiveness were evaluated in 10 clinical trials that enrolled 5,400 patients with type 2 diabetes. In these trials, Adlyxin was evaluated both as a standalone therapy and in combination with other FDA-approved diabetic medications, including metformin, sulfonylureas, pioglitazone and basal insulin. Use of Adlyxin improved hemoglobin A1c levels (a measure of blood sugar levels) in these trials.

In addition, more than 6,000 patients with type 2 diabetes at risk for atherosclerotic cardiovascular disease were treated with either Adlyxin or a placebo in a cardiovascular outcomes trial. Use of Adlyxin did not increase the risk of cardiovascular adverse events in these patients.

Adlyxin should not be used to treat people with type 1 diabetes or patients with increased ketones in their blood or urine (diabetic ketoacidosis).

The most common side effects associated with Adlyxin are nausea, vomiting, headache, diarrhea and dizziness. Hypoglycemia in patients treated with both Adlyxin and other antidiabetic drugs such as sulfonylurea and/or basal insulin is another common side effect. In addition, severe hypersensitivity reactions, including anaphylaxis, were reported in clinical trials of Adlyxin.

The FDA is requiring the following post-marketing studies for Adlyxin:

  • Clinical studies to evaluate dosing, efficacy and safety in pediatric patients.
  • A study evaluating the immunogenicity of lixisenatide.

Adlyxin is manufactured by Sanofi-Aventis U.S. LLC, of Bridgewater, New Jersey.


Asthma Pill shows massive promise!

Posted on Updated on

The first new asthma pill in two decades has just completed its third phase of clinical trials, and not only did patients report instant relief – the pill actually started to repair the lining of their airways.

Taken twice daily, the pill was shown to reduce inflammation by 80 percent in people with moderate-to-severe asthma.  

“This research shows massive promise and should be greeted with cautious optimism,” said Samantha Walker from charity organisation Asthma UK, which was not involved in the research. “The possibility of taking a pill instead of using an inhaler will be a very welcome one among the 5.4 million people in the UK with asthma.”

Researchers from Leicester University in the UK just finished testing the drug, called Fevipiprant, in a phase-III trial. This means it’s already passed phase-I and phase-II trials, which assess safety and severe side effects, and also short-term results on a small group of patients. 

The trial involved 61 participants, split into two groups. One group was given 225 mg of the drug twice a day for 12 weeks, and the other were assigned a placebo. Both the Fevipiprant and placebos were taken with existing asthma medications, rather than replacing them. 

The effects were tested via a series of breathing tests, airway tissue samples, and CT scans of the chest, but one of the main aims of the trial was to observe the effect of Fevipiprant on the patients’ airway inflammation – typically measured via something called sputum eosinophil count.

As the researchers explain, the sputum eosinophil count measures inflammation by detecting levels of a specific type of white blood cell that’s associated with asthma, and is found in higher levels the more severe the condition.

As a baseline, people who don’t have asthma will have less than 1 percent sputum eosinophil count, while those with moderate-to-severe asthma usually have a reading of about 5 percent.

“The rate in people with moderate-to-severe asthma taking [Fevipiprant] was reduced from an average of 5.4 percent to 1.1 percent over 12 weeks,” the researchers report in a press release.

The researchers say that this progressive effect, plus indications that the drug was actually repairing damaged airway tissue, could allow patients with severe asthma to stop taking strong medications to deal with their disease.

“I’m really excited by this because this is the first treatment that I’m aware of that has been able to show effects across the board,” lead researcher Chris Brightling told Denis Campbell at The Guardian.

“I’m excited by how effective it’s likely to be and also about its potential to reduce the need for patients to take oral steroids. Those people would be able to stop taking those drugs, which would make a huge difference to them.”

Of course, there’s still a long way to go before we’ll see the drug on the market – if it even makes it. Brightling told The Guardian, “more than two but less than three years’ time”, if everything goes to plan. 

He’s now preparing for another clinical trial involving 850 patients, and results are expected some time in 2018. Other studies are also reportedly in the planning stages. 

Let’s hope this drug continues to live up to its promise to give asthmatics a better option – or at least sparks more research in an area that’s been dormant for too long.

The results of the trial have been published in Lancet Respiratory Medicine.

Source: 1

USFDA approves first Clinical Trial on Zika Vaccine

Posted on Updated on

The US Food and Drug Administration (FDA) has approved the first human tests of an experimental Zika virus vaccine, the makers of the drug announced on Monday.

Called GLS–5700, the medication will be used in a clinical trial involving 40 healthy people, and represents the first major step towards ultimately immunising people against Zika – which was declared a global public health emergency by the World Health Organisation (WHO) in February.

“We are proud to have attained the approval to initiate the first Zika vaccine study in human volunteers,” said J. Joseph Kim, president and CEO of US-based Inovio Pharmaceuticals, which is developing the vaccine with South Korean partner, GeneOne Life Science. “We plan to dose our first subjects in the next weeks and expect to report phase 1 interim results later this year.”

GLS–5700 works by stimulating the body’s immune system to defend itself against Zika. Synthetic fragments of viral DNA are injected into the skin, prompting the immune system’s T cells to generate antibodies to fight the infection.

The news of the vaccine trial comes two months after the US Centres for Disease Control and Prevention (CDC) confirmed the causative link between the infection and birth defects such as microcephaly, and represents the culmination of an intense nine months of vaccine development, during which global fears over Zika’s spread have only grown.

“As of May 2016, 58 countries and territories reported continuing mosquito-borne transmission of the Zika virus,” said Kim. “[T]he incidences of viral infection and medical conditions caused by the virus are expanding, not contracting.”

It’s worth pointing out that just because GLS–5700 has reached human testing, there’s no guarantee it will turn out to safely immunise people against Zika. The vaccine has been tested successfully in small and large animal models, but clinical trials in humans could take several years to demonstrate that the treatment is safe, and there’s no guarantee it will ultimately prove effective or make it through subsequent testing phases.

But fortunately, GLS–5700 isn’t the only Zika vaccine candidate currently in development. An Indian company called Bharat Biotech is researching Zika vaccine development in animals, while French pharmaceutical company Sanofi SA is expected to begin human trials with one of its drugs later this year.

In the US, the National Institute of Allergy and Infectious Diseases (NIAID) says it’s expecting to shortly receive FDA approval to trial a separate vaccine candidate it developed itself, which would mean we could have two vaccines in human testing in a matter of weeks.

Earlier in the month, scientists from the University of Texas Medical Centre published findings on how a protein called interferon-induced protein 3 could help reduce Zika’s ability to infect brain cells – although clinical trials may be a while away for that particular treatment.

Even though there’s a huge amount of hurdles and potential roadblocks facing all of these vaccine trials, there’s reason to have hope.

“Always, the first vaccine to go into clinical trial is important,” epidemiologist Anna Durbin from Johns Hopkins University, who is involved with the NIAID vaccine effort, told Jessica Glenza at The Guardian.

“It means the FDA has reviewed it, and I’m sure is formulating questions and getting ready for additional candidates to submit their investigational drug applications,” she added. “It shows progress and momentum, and we just need to keep momentum going.”

Source: 1